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Abstract: Highly optically enriched protected nitrogenated heterocycles with different ring sizes 
have been synthesized by a very efficient methodology consisting in the asymmetric transfer 
hydrogenation of N-(tert-butylsulfinyl)haloimines followed by treatment with a base to promote an 
intramolecular nucleophilic substitution process. N-Protected aziridines, pyrrolidines, piperidines 
and azepanes bearing aromatic, heteroaromatic and aliphatic substituents have been obtained in very 
high yields and diastereomeric ratios up to > 99:1. The free heterocycles can be easily obtained by a 
simple and mild desulfinylation procedure. Both enantiomers of the free heterocycles can be 
prepared with the same good results by changing the absolute configuration of the sulfur atom of the 
sulfinyl group. 
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Introduction 
The synthesis of chiral nitrogen-containing saturated heterocycles has attracted the attention of 
organic chemists worldwide.1 Some features of those compounds that make them so interesting are: 
(a) they are key structures present in many natural and synthetic products that display biological and 
pharmacological activity,2 playing a crucial role in the design of new drugs; (b) they have found 
applications as either chiral ligands or organocatalysts in asymmetric synthesis.3 Among the 
different methods to build those heterocyclic scaffolds in enantiomerically enriched form, the 
cyclization of chiral haloamines has shown to be very straightforward and effective. The precursor 
haloamines can be synthesized by addition or reduction methodologies from imines bearing a chiral 
auxiliary bonded to the nitrogen atom. In recent years, the tert-butylsulfinyl group has arisen as an 
outstanding chiral auxiliary that leads to excellent diastereoselectivities in a wide assortment of 
synthetic approaches4 and shows the advantage of an easy removal from the nitrogen atom under 
mild acidic conditions.5 The asymmetric synthesis of saturated nitrogenated heterocycles from N-
(tert-butylsulfinyl)haloimines has been accomplished through addition of nucleophiles to the iminic 
carbon6 or, to a lesser extent, via reduction of the C=N bond with either boron or aluminium 
hydrides.7 
Functionalized amines are appropriate substrates for the preparation of nitrogenated heterocycles.1 
A very useful methodology for the stereoselective synthesis of chiral amines is the asymmetric 
transfer hydrogenation (ATH) of imines.8 However, this reduction procedure has seldom been used 
as a tool to prepare nitrogenated heterocycles and, to the best of our knowledge, there are only a few 
examples reported so far which consist in the reduction of other unsaturated heterocyclic compounds 
containing endocyclic imine functions.9 In the last years, several of our research activities have 
focused on diastereoselective processes using enantiomerically pure N-(tert-butylsulfinyl)imines as 
substrates.10 We have developed a very effective method for the preparation of highly 
enantiomerically enriched aromatic and aliphatic amines by ruthenium-catalyzed ATH of N-(tert-
butylsulfinyl)ketimines in isopropyl alcohol followed by desulfinylation of the nitrogen atom.11 
Recently, we have used this hydrogen transfer based reduction methodology as a key step to 
accomplish the synthesis of optically enriched γ-, δ-, and ε-lactams from N-(tert-
butylsulfinyl)iminoesters.12 Herein we describe the application of the ATH of N-(tert-
butylsulfinyl)haloimines to the synthesis of highly enantiomerically enriched aziridines, 
pyrrolidines, piperidines and azepanes. 
 
Results and Discussion 
Encouraged by the excellent results that we had obtained in the synthesis of enantiomerically 
enriched amines through a ruthenium-catalyzed ATH of sulfinylimines,11 we decided to try to extend 
this methodology to the diastereoselective reduction of N-(tert-butylsulfinyl)ketimines 2 bearing 
halogen atoms that could later act as leaving groups in intramolecular nucleophilic substitution 
processes that would lead to N-protected saturated heterocycles 4 (Scheme 1). Since the sulfinyl 
group can easily be removed,5 this sequence would represent an interesting way of preparing 
nitrogenated heterocyclic compounds. 
 
Scheme 1. Blueprint for the Preparation of Chiral Saturated N-Protected Heterocycles 4 
  
Our first goal was the synthesis of haloimines 2, for which we needed the corresponding 
haloketones 1 as precursors. Chart 1 shows all the haloketones that we have used, some of which 
were commercially available (1a-1d, 1g, 1h, 1k and 1m). Chloroketones 1e, 1f, 1i, 1j, 1l and 1n and 
bromoketones 1n’ and 1o’ were prepared from halogen-containing acid chlorides 5 as indicated in 
Scheme 2. First, the acid chlorides were transformed into the corresponding Weinreb amides 6, 
which reacted with several Grignard reagents to give, after hydrolysis, the expected haloketones 1e, 
1f, 1i, 1j, 1l, 1n, 1n’ and 1o’ in 61-93% overall yields. The starting acid chlorides were 
commercially available, except for the one bearing a bromine atom, which was prepared by 
treatment of the corresponding carboxylic acid with thionyl chloride. 
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1g: R = 4-FC6H4
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1i: R = 2-thienyl
1j: R = i-Pr
1k: R = Ph
1l: R = 3-MeC6H4
1m: R = Me  
 
Scheme 2. Preparation of Haloketones 1e, 1f, 1i, 1j, 1l, 1n, 1n’ and 1o’ 
  
Having all the haloketones 1 in hand, the required haloimines 2 were prepared by condensation of 
those haloketones with (R)-2-methylpropane-2-sulfinamide in the presence of titanium tetraethoxide 
under neat conditions (Scheme 3), following our reported procedure.13 Thereby, the expected 
enantiomerically pure (R)-N-(tert-butylsulfinyl)haloimines 2 were isolated in good yields after 
column chromatography. In the case of the aliphatic imine 2m, an 86:14 (E/Z) mixture of 
geometrical isomers was obtained, from which the pure (E) isomer was isolated after column 
chromatography. The (S)-haloimine ent-2e was also prepared by the same procedure but using the 
(S) enantiomer of 2-methylpropane-2-sulfinamide. Unfortunately, all attempts to prepare -
haloimines failed due to elimination processes that led to ,-unsaturated imines, together with some 
unreacted -haloketones. 
 
Scheme 3. Synthesis of Haloimines 2 and ent-2ea 
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a In parentheses, yield of isolated product after column chromatography (silica gel, hexane/ethyl acetate) based on the 
starting haloketones 1. All isolated haloimines 2 and ent-2e were ≥ 95% pure (300 MHz 1H NMR). 
b  (S)-2-methylpropane-2-sulfinamide was used in this case. 
c A mixture of geometrical isomers with an estimated E/Z ratio = 86:14 was obtained in the crude reaction mixture. The 
(E) isomer could be separated in pure form by column chromatography (silica gel, hexane/ethyl acetate) in 27% yield. 
 
Once we had obtained haloimines 2, we tried to reduce them employing our hydrogen transfer 
methodology. Haloimine 2e was chosen as a model substrate and it was submitted to our optimal 
reaction conditions for the ATH of N-(tert-butylsulfinyl)ketimines:11c,d isopropyl alcohol as a 
hydrogen source, a ruthenium catalyst prepared from [RuCl2(p-cymene)]2 and the achiral ligand 2-
amino-2-methylpropan-1-ol and a reaction temperature of 50 ºC. Under these conditions, the 
reduction of compound 2e was complete in 2 h. At this time, a 0.3 M solution of tert-BuOK in 
isopropyl alcohol was added to the reaction flask and the mixture was stirred at 50 ºC for 1 h in order 
to attempt the one-pot cyclization. Gratifyingly, the 1H NMR spectrum of the reaction crude showed 
that the N-sulfinyl pyrrolidine 4e (Scheme 4) was the major product, with an estimated 
diastereomeric ratio of 99:1. After column chromatography, pyrrolidine 4e was isolated in 90% 
yield. In order to validate the dr value estimated by 1H NMR, haloimine ent-2e was submitted to the 
same one-pot ATH-cyclization sequence and product ent-4e was obtained with a dr > 99:1 
(according to the 1H NMR spectrum of the reaction crude) and in 91% yield. Desulfinylation of both 
4e and ent-4e by treatment with a solution of HCl in MeOH led to the corresponding free 
pyrrolidines 7e and ent-7e (Chart 2) in almost quantitative yields, which were then benzoylated and 
analyzed by HPLC, giving ee values of 98% (for benzoylated 7e) and 99% (for benzoylated ent-7e) 
(see the Supporting Information for details). These enantiomeric excesses match very well with the 
diastereomeric ratios previously estimated by 1H NMR for compounds 4e and ent-4e. Therefore, the 
estimation by 1H NMR seems to be an appropriate way to determine the diastereoselectivities of 
these ATH processes. The absolute configurations of pyrrolidines 7e and ent-7e were determined by 
comparison of the sign of their optical rotation values with the ones reported in the literature.7c As it 
was the case in our ATH of simple ketimines, (R)-configurated haloimines 2 led to (R)-configurated 
nitrogenated heterocycles. 
 
Chart 2 
 
 
Next, we studied the reaction scope by applying our one-pot ATH-cyclization sequence to 
haloimines 2d-2j (Scheme 4) with the aim of preparing some other substituted pyrrolidines. N-
protected pyrrolidines bearing phenyl substituents with either electron-releasing (4f) or electron-
withdrawing groups (4g) could be prepared with excellent results. We were able to get a single 
crystal of compound 4g and the corresponding X-ray structure confirmed that the stereogenic center 
generated in the ATH process had the (R) absolute configuration (see Figure 1).  
 
Scheme 4. One-pot ATH-Cyclization Sequence. Synthesis of N-Protected Aziridines 4a-4c and 
Pyrrolidines 4d-4j and ent-4ea 
 
 
a In parentheses, yield of isolated product after column chromatography (based on the starting haloimine 2 or ent-2e) and 
diastereomeric ratio (estimated from the 1H NMR spectrum of the crude reaction mixture). All isolated compounds 4 
and ent-4e were ≥ 95% pure (300 MHz 1H NMR). 
b [RuCl2(p-cymene)]2 (5 mol%), 2-amino-2-methylpropan-1-ol (10 mol%) and tert-BuOK (25 mol%) were used in this 
reaction. 
c (S)-Chloroimine ent-2e was used as substrate in this reaction. 
 
 
Figure 1. X-Ray Structure of Compound 4g (for an ORTEP plot and detailed crystallographic 
information, see the Supporting Information) 
 
Other pyrrolidines with aromatic substituents different from phenyl, such as 2-naphthyl (4h) or 2-
thienyl (4i), could be prepared with equal efficiency. According to our previous observations,11d,12 
the catalyst loading for the reduction of the aliphatic imine 2j had to be increased to assure full 
conversion of the starting material,14 but it is worth noting that the expected aliphatic pyrrolidine 4j 
was obtained in 90% yield with a 98:2 dr. 
This one-pot ATH-cyclization routine was also applied to -chloroimines 2a-2c in order to try to 
synthesize the corresponding chiral aziridines (Scheme 4). We were glad to see that N-protected 3-
membered ring heterocycles with either aromatic (4a and 4b) or aliphatic substituents (4c) could be 
obtained in high yields and diastereomeric ratios. As before, a higher catalyst loading was necessary 
to achieve complete reduction of the aliphatic imine 2c.14  
These promising results encouraged us to try to extend this one-pot ATH-cyclization protocol to 
the synthesis of piperidines and azepanes from the corresponding - and -haloimines, respectively. 
However, the cyclization did not take place under those reaction conditions: when we used -
chloroimine 2k as substrate, the corresponding chlorosulfinamide 3k was obtained instead of the 
expected piperidine.15 Fortunately, a two-step procedure allowed the formation of N-protected 
piperidine 4k: when the ATH reaction was finished, the usual work-up was performed11c,d and the 
crude residue was dissolved in THF, KHMDS was added at 0 ºC and the mixture was stirred at the 
same temperature for 1 h. Under these conditions, a highly optically enriched piperidine 4k was 
isolated in 91% overall yield (Scheme 5). The same two-step methodology applied to imine 2l 
yielded compound 4l with the same good results concerning both yield and diastereoselectivity. It is 
worth noting that the protected aliphatic piperidine 4m could also be obtained with a 97:3 dr using 
the same amount of catalyst as for the reduction of the other aliphatic imines 2c and 2j.16 
 
Scheme 5. ATH Followed by Treatment with KHMDS. Synthesis of Piperidines 4k-4m and 
Azepanes 4n, 4oa 
 
 
a In parentheses, yield of isolated product after column chromatography (based on the starting haloimine 2) and 
diastereomeric ratio (estimated from the 1H NMR spectrum of the crude reaction mixture). All isolated compounds 4 
were ≥ 95% pure (300 MHz 1H NMR). 
b The ATH crude was dissolved in anhydrous THF, KHMDS (1.3 equiv, 1 M solution in THF) was added at 0 ºC and the 
reaction mixture was stirred at the same temperature for 1 h. 
c [RuCl2(p-cymene)]2 (5 mol%), 2-amino-2-methylpropan-1-ol (10 mol%) and tert-BuOK (25 mol%) were used in this 
reaction. 
d The ATH crude was dissolved in anhydrous THF, KHMDS (1.3 equiv, 1 M solution in THF) was added at 0 ºC and the 
reaction mixture was stirred allowing it to reach room temperature and then stirred overnight. 
 
The two-step procedure did not work for the preparation of 7-membered ring heterocycles from -
chloroimine 2n. Treatment of chlorosulfinamide 3n with KHMDS failed to form the cyclization 
product, even at higher temperatures and increasing the amount of base. Fortunately, this problem 
could be solved by starting from imines 2n’ and 2o’, both having a bromine atom as a leaving group 
instead of a chlorine. Treatment of bromine-containing sulfinamides 3n’ and 3o’ with KHMDS 
overnight at room temperature led to the corresponding azepanes 4n and 4o in high yields and with 
excellent diastereoselectivities (Scheme 5). We were able to get an X-ray structure of compound 4n, 
which confirmed that the stereogenic center generated in the ATH process had the (R) absolute 
configuration (Figure 2). To the best of our knowledge, the synthesis of azepanes through ATH 
processes had never been reported so far. 
 
 
Figure 2. X-Ray Structure of Compound 4n (for an ORTEP plot and detailed crystallographic 
information, see the Supporting Information) 
 
In our opinion, the methodology described herein represents a very efficient route to prepare 
saturated nitrogenated heterocycles from halogen-containing N-(tert-butylsulfinyl)ketimines and 
presents some advantages in comparison with the few procedures found in the literature that allow a 
similar transformation:7 (a) we use a catalytic ATH method to reduce the imine function, while the 
reported procedures employ stoichiometric reagents such as boron or aluminium hydrides which 
could lead to the formation of side products; (b) the achiral ligand that we use in the ruthenium 
catalyst is very cheap, thus reducing the reaction costs; (c) isopropyl alcohol, which acts as a solvent 
and as a hydrogen source in our ATH reaction, is environmentally friendly and is a convenient 
solvent for industrial scale processes;17 (d) our methodology is more versatile, since we have been 
able to prepare nitrogenated heterocycles with a variety of ring sizes. 
 
Conclusion 
We have presented herein a simple, versatile and very effective procedure for the synthesis of 
highly optically enriched N-protected aziridines, pyrrolidines, piperidines and azepanes by applying 
our ATH protocol to the diastereoselective reduction of N-(tert-butylsulfinyl)haloimines. A one-pot 
ATH-cyclization sequence enables the preparation of both aziridines and pyrrolidines, whilst 
piperidines and azepanes become accessible through a two-step protocol. The free saturated 
nitrogenated heterocycles can be easily obtained by removal of the sulfinyl group from the nitrogen 
atom under mild acidic conditions. Nitrogenated heterocycles bearing aromatic, heteroaromatic or 
aliphatic substituents can be prepared in very high yields and optical purities. The absolute 
configuration of the final product can be tuned up simply by choosing the adequate configuration on 
the sulfinyl chiral auxiliary. 
 
Experimental Section 
General Information 
All glassware was dried in an oven at 100 ºC and cooled to room temperature under argon before 
use. All reactions were carried out under an argon atmosphere. Haloketones 1a-1d, 1g, 1h, 1k and 
1m, (R)- and (S)-tert-BuSONH2, Ti(OEt)4 (33% TiO2 min), [RuCl2(p-cymene)]2, 2-amino-2-
methylpropan-1-ol and all the starting materials needed for the synthesis of haloketones 1e, 1f, 1i, 1j, 
1l, 1n, 1n’ and 1o’ were commercially available and were used as received. tert-BuOK was heated 
in a Kugel-Rohr distillation apparatus at 170-180 °C under vacuum for 4 h before use. Commercially 
available 4 Å molecular sieves were dried in a Kugel-Rohr distillation apparatus at 120 ºC under 
vacuum for 5h before use. Commercially available anhydrous isopropyl alcohol was used as solvent 
in all the transfer hydrogenation reactions. Column chromatography was performed with silica gel 
60 of 230–400 mesh. Thin layer chromatography (TLC) was performed on precoated silica gel 
plates; detection was done by UV254 light and staining with phosphomolybdic acid (solution of 1 g 
of phosphomolybdic acid in 24 mL of absolute ethanol); Rf values are given under these conditions. 
Melting points (mp) are uncorrected. Unless otherwise stated, NMR samples were prepared using 
CDCl3 as solvent. The internal references used for NMR spectra were tetramethylsilane (TMS) for 
1H NMR and CDCl3 for 13C NMR; chemical shifts are given in  (ppm) and coupling constants (J) in 
Hz. 13C NMR assignments were made on the basis of DEPT experiments. Infrared (FT-IR) spectra 
were obtained on a spectrophotometer equipped with an attenuated total reflectance (ATR) 
accessory. Mass spectra (EI) were obtained at 70 eV; fragment ions in m/z with relative intensities 
(%) in parenthesis are given. HRMS were measured with electron impact (EI) ionization at 70 eV 
and a double focusing mass analyzer (magnetic and electric fields). Optical rotation measurements 
and HPLC analyses were performed at 20 ºC. 
 
Preparation of Weinreb Amides 6. General Procedure 
A 2 M NaOH aqueous solution (15 mL) was added to a suspension of Me(MeO)NH·HCl (926 mg, 
9.5 mmol) in CH2Cl2 (15 mL) at 0 ºC. Then, the corresponding acid chloride (10.0 mmol) was added 
dropwise during ca. 1 min, the reaction mixture was allowed to reach room temperature and it was 
stirred overnight. The reaction mixture was extracted with CH2Cl2 (2 × 5 mL) and the combined 
organic layers were washed with a 2 M NaOH aqueous solution (10 mL) and dried (Na2SO4). After 
filtration and evaporation of the solvents, the expected Weinreb amides were obtained, which were 
used in the next step without purification. 
For the preparation of bromoketones 1n’ and 1o’, 6-bromohexanoyl chloride was required, which 
was prepared by refluxing a mixture of 6-bromohexanoic acid (2.34 g, 12.0 mmol) and SOCl2 (60.0 
mmol) in CH2Cl2 (20 mL) for 5 h. Solvent and the excess of SOCl2 were evaporated and the residue 
was used directly for the synthesis of the corresponding Weinreb amide. 
 
Addition of Grignard Reagents to Weinreb Amides 6. Synthesis of Haloketones 1e, 1f, 1i, 1j, 
1l, 1n, 1n’ and 1o’. General Procedure 
A solution of the Grignard reagent18 (16.0 mmol) was added dropwise over a period of 40 minutes 
with the aid of a syringe pump to a solution of the corresponding Weinreb amide (8.0 mmol) in 
anhydrous Et2O (30 mL) at −40 ºC with vigorous stirring, and the mixture was stirred at the same 
temperature for 1 h. The temperature was slowly risen to room temperature (by switching the 
cryostat off and keeping the reaction flask inside the cooling bath) and the reaction was stirred 
overnight. Then, a saturated aqueous NH4Cl solution (25 mL) was carefully added (in small portions 
and cooling the flask at 0 ºC) and the mixture was extracted with Et2O (3 × 15 mL). The combined 
organic layers were dried (Na2SO4). After filtration and evaporation of the solvent, the resulting 
residue was purified by column chromatography (silica gel, hexane/ethyl acetate), giving the 
expected haloketones 1e (1.416 g, 90%), 1f (1.565 g, 92%), 1i (1.328 g, 88%), 1j (0.725 g, 61%), 1l 
(1.466 g, 87%), 1n (1.568 g, 93%), 1n’ (1.837 g, 90%) and 1o’ (1.939 g, 85%). Compounds 1e,19 
1f,19 1i,20 1j,21 1n22 and 1n’23 were identified by comparison of their physical and spectroscopic data 
with the ones reported in the literature. The corresponding physical, spectroscopic and analytical 
data for haloketones 1l and 1o’ follow. 
 
5-Chloro-1-(3-methylphenyl)pentan-1-one (1l): colorless oil; Rf 0.56 (hexane/ethyl acetate: 9/1); 
IR (neat) 3058, 1683 cm-1; 1H NMR (300 MHz, CDCl3) δ 1.77-2.00 (4H, m), 2.41 (3H, s), 3.00 (2H, 
t, J = 7.0 Hz), 3.58 (2H, t, J = 6.3 Hz), 7.29-7.41 (2H, m), 7.67-7.79 (2H, m); 13C NMR (75 MHz, 
CDCl3) δ 21.3, 21.5, 32.0, 37.5, 44.7, 125.2, 128.4, 128.5, 133.8, 136.8, 138.4, 199.8; m/z 212 (M+ + 
2, 2%), 210 (M+, 7%), 134 (25), 119 (100), 91 (29); HRMS: M+ found 210.0817, C12H15ClO 
requires 210.0811. 
 
6-Bromo-1-(3-methoxyphenyl)hexan-1-one (1o’): white solid; mp 52 °C; Rf 0.50 (hexane/ethyl 
acetate: 9/1); IR (neat) 3054, 1683, 1255 cm-1; 1H NMR (300 MHz, CDCl3) δ 1.47-1.63, 1.73-1.83, 
1.88-1.97 (2H each, 3 m), 2.99 (2H, t, J = 7.3 Hz), 3.44 (2H, t, J = 6.8 Hz), 3.86 (3H, s), 7.11 (1H, 
ddd, J = 8.1, 2.7, 0.9 Hz), 7.38 (1H, t, J = 8.1 Hz), 7.49 (1H, dd, J = 2.7, 1.5 Hz), 7.54 (1H, m); 13C 
NMR (75 MHz, CDCl3) δ 23.3, 27.8, 32.6, 33.6, 38.4, 55.4, 112.2, 119.4, 120.6, 129.5, 138.3, 159.8, 
199.8; m/z 286 (M+ + 2, 9%), 284 (M+, 9%), 205 (48), 176 (100), 107 (26); HRMS: M+ found 
284.0415, C13H17BrO2 requires 284.0412. 
 
Synthesis of Haloimines 2 and ent-2e. General Procedure 
N-(tert-Butylsulfinyl)haloimines were prepared by condensation of the corresponding haloketones 
1 with (R)-2-methylpropane-2-sulfinamide (for 2) or (S)-2-methylpropane-2-sulfinamide (for ent-2e) 
following our recently reported procedure,13 as follows: a mixture of haloketone 1 (5.0 mmol), (R)- 
or (S)-tert-BuSONH2 (612 mg, 5.0 mmol) and Ti(OEt)4 (2.1 mL, 10.0 mmol) was stirred overnight 
under argon at 72 ºC (oil bath temperature). After cooling to room temperature, the mixture was 
diluted with ethyl acetate (10 mL) and poured into brine (3 mL) while rapidly stirring. The resulting 
suspension was filtered through a plug of celite and the filter cake was washed with ethyl acetate. 
After evaporation of the solvent, the resulting residue was purified by column chromatography 
(silica gel, hexane/ethyl acetate), to give the expected haloimines 2 and ent-2e in the yields indicated 
in Scheme 3. Compounds 2a,11b 2d,7d 2e,7c ent-2e,7c 2f,7d 2g,7d 2i,7d 2k,7d and 2n7d were identified by 
comparison of their physical and spectroscopic data with the ones reported in the literature. The 
corresponding physical, spectroscopic and analytical data for haloimines 2b, 2c, 2h, 2j, 2l, 2m, 2n’ 
and 2o’ follow. 
 
(R)-N-[2-Chloro-1-(4-chlorophenyl)ethyliden]-2-methylpropane-2-sulfinamide (2b): yellow oil; 
Rf 0.69 (hexane/ethyl acetate: 2/1); [α]D20 –20.0 (c 1.2, CH2Cl2); IR (neat) 3070, 1576, 1070 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 1.36 (9H, s), 5.00, 5.14 (1H each, 2 d, J = 11.0 Hz each), 7.43, 7.81 (2H 
each, 2 d, J = 8.6 Hz each); 13C NMR (100 MHz, CDCl3) δ 23.2, 35.2, 59.8, 128.8, 129.0, 134.3, 
138.3, 168.2; m/z (DIP) 291 (M+, <1%), 237 (32), 235 (47), 201 (20), 199 (56), 151 (14), 138 (27), 
137 (20), 57 (100); HRMS: M+ ‒ C4H8 found 234.9638, C8H7Cl2NOS requires 234.9625. 
 
(R)-N-[1-Chloro-3,3-dimethyl-2-butyliden]-2-methylpropane-2-sulfinamide (2c): yellow oil; Rf 
0.54 (hexane/ethyl acetate: 4/1); [α]D20 ‒426.0 (c 1.2, CH2Cl2); IR (neat) 3068, 1601, 1076 cm-1; 1H 
NMR (300 MHz, CDCl3) δ 1.23 (9H, s), 1.29 (9H, s), 4.25, 4.92 (1H each, 2 d, J = 10.5 Hz each); 
13C NMR (75 MHz, CDCl3) δ 22.7, 27.6, 34.3, 43.1, 58.0, 182.8; m/z (DIP) 237 (M+, <1%), 183 
(15), 181 (38), 120 (17), 118 (53), 83 (41), 57 (100); HRMS: M+ found 237.0970, C10H20ClNOS 
requires 237.0954. 
 
(R)-N-[4-Chloro-1-(2-naphthyl)butyliden]-2-methylpropane-2-sulfinamide (2h): yellow oil; Rf 
0.41 (hexane/ethyl acetate: 4/1); [α]D20 +31.0 (c 1.7, CH2Cl2); IR (neat) 3058, 1588, 1065 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 1.37 (9H, s), 2.14-2.32 (2H, m), 3.32-3.63 (2H, m), 3.66-3.71 (2H, m), 
7.51-7.60 (2H, m), 7.86 (2H, d, J = 8.6 Hz), 7.93, 8.02 (1H each, 2 d, J = 7.6 Hz each), 8.33 (1H, s); 
13C NMR (100 MHz, CDCl3) δ 22.7, 29.9, 31.8, 44.8, 57.9, 124.0, 126.7, 127.6, 128.0, 128.2, 128.4, 
129.3, 132.7, 134.7, 134.8, 177.8; m/z (DIP) 335 (M+, <1%), 281 (17), 279 (46), 196 (13), 169 (100), 
154 (23), 153 (21), 127 (23), 57 (15); HRMS: M+ found 335.1122, C18H22ClNOS requires 335.1111. 
 
(R)-N-(6-Chloro-2-methyl-3-hexyliden)-2-methylpropane-2-sulfinamide (2j): yellow oil; Rf 0.35 
(hexane/ethyl acetate: 85/15); [α]D20 ‒120.5 (c 1.8, CH2Cl2); IR (neat) 1620, 1069 cm-1; 1H NMR 
(300 MHz, CDCl3) δ 1.14 (6H, d, J = 6.8 Hz), 1.24 (9H, s), 2.04-2.14 (2H, m), 2.45-3.05 (3H, m), 
3.59 (2H, t, J = 6.1 Hz); 13C NMR (75 MHz, CDCl3) δ 20.1, 20.2, 22.3, 30.6, 32.4, 39.5, 44.5, 56.9, 
190.0; m/z (DIP) 251 (M+, <1%), 197 (35), 195 (100), 161 (21), 110 (43), 57 (71); HRMS: M+ found 
251.1118, C11H22ClNOS requires 251.1111. 
 
(R)-N-[5-Chloro-1-(3-methylphenyl)pentyliden]-2-methylpropane-2-sulfinamide (2l): yellow 
oil; Rf 0.31 (hexane/ethyl acetate: 4/1);  [α]D20 ‒18.5 (c 1.9, CH2Cl2);  IR (neat) 3055, 1573, 1070 
cm-1; 1H NMR (400 MHz, CDCl3) δ 1.33 (9H, s), 1.76-1.97 (4H, m), 2.40 (3H, s), 3.07-3.41 (2H, 
m), 3.58-3.73 (2H, m), 7.29-7.38, 7.54-7.73 (2H each, 2 m); 13C NMR (100 MHz, CDCl3) δ 21.5, 
22.7, 25.9, 31.4, 32.2, 44.3, 57.6, 124.5, 127.9, 128.5, 132.3, 137.4, 138.3, 179.3; m/z (DIP) 313 
(M+, <1%), 259 (36), 257 (100), 240 (21), 174 (23), 146 (37), 118 (26), 57 (23); HRMS: M+ found 
313.1278, C16H24ClNOS requires 313.1267. 
 
(R,E)-N-(6-Chloro-2-hexyliden)-2-methylpropane-2-sulfinamide (2m):24 yellowish oil; Rf 0.61 
(hexane/ethyl acetate: 1/1); [α]D20 –145.0 (c 1.3, CH2Cl2); IR (neat) 1622, 1070 cm-1; 1H NMR (300 
MHz, CDCl3) δ 1.24 (9H, s), 1.67-1.88 (4H, m), 2.33 (3H, s), 2.37-2.52 (2H, m), 3.55 (2H, t, J = 6.1 
Hz); 13C NMR (75 MHz, CDCl3) δ 22.1, 22.5, 23.0, 31.7, 42.2, 44.6, 56.2, 184.6; m/z (DIP) 237 
(M+, <1%), 183 (31), 181 (100), 147 (11), 57 (48). 
 
(R)-N-(6-Bromo-1-phenylhexyliden)-2-methylpropane-2-sulfinamide (2n’): yellow oil; Rf 0.43 
(hexane/ethyl acetate: 4/1); [α]D20 ‒20.0 (c 1.2, CH2Cl2); IR (neat) 3056, 1590, 1070 cm-1; 1H NMR 
(300 MHz, CDCl3) δ 1.33 (9H, s), 1.52-1.75 (4H, m), 1.85-1.94 (2H, m), 3.09-3.33 (2H, m), 3.40 
(2H, t, J = 6.7 Hz), 7.38-7.52 (3H, m), 7.84 (2H, d, J = 7.1 Hz); 13C NMR (75 MHz, CDCl3) δ 22.7, 
27.8, 28.3, 32.15, 32.2, 33.6, 57.6, 127.4, 128.6, 131.5, 137.7, 179.5; m/z (DIP) 357 (M+, <1%), 303 
(100), 301 (98), 252 (10), 174 (28), 167 (19), 132 (30), 119 (25), 104 (34), 103 (24), 77 (14), 57 
(32); HRMS: M+ found 357.0777, C16H24BrNOS requires 357.0762. 
 
(R)-N-[6-Bromo-1-(3-methoxyphenyl)hexyliden]-2-methylpropane-2-sulfinamide (2o’): yellow 
oil; Rf 0.35 (hexane/ethyl acetate: 4/1); [α]D20 ‒2.0 (c 1.6, CH2Cl2); IR (neat) 3075, 1604, 1572, 1073 
cm-1; 1H NMR (400 MHz, CDCl3) δ 1.33 (9H, s), 1.51-1.62, 1.64-1.76, 1.84-1.94 (2H each, 3 m), 
3.06-3.34 (2H, m), 3.40 (2H, t, J = 6.7 Hz), 3.84 (3H, s), 7.03 (1H, d, J = 7.5 Hz), 7.35 (1H, t, J = 
8.1 Hz), 7.37-7.51 (2H, m); 13C NMR (100 MHz, CDCl3) δ 22.6, 27.8, 28.2, 32.1, 32.2, 33.5, 55.3, 
57.6, 112.8, 117.0, 119.7, 129.5, 139.1, 159.6, 179.2; m/z (DIP) 387 (M+, <1%), 333 (56), 331 (55), 
316 (25), 314 (24), 149 (100), 134 (20), 57 (22); HRMS: M+ found 387.0870, C17H26BrNO2S 
requires 387.0868. 
 
One-Pot ATH-Cyclization Sequence. Synthesis of Aziridines 4a-4c and Pyrrolidines 4d-4j 
and ent-4e. General Procedure 
A mixture of [RuCl2(p-cymene)]2 (14 mg, 0.023 mmol), 2-amino-2-methylpropan-1-ol (4 mg, 
0.045 mmol), 4 Å molecular sieves (0.3 g), and anhydrous i-PrOH (1.5 mL) under argon was heated 
up to 90 °C (oil bath temperature) for 20 min {for aliphatic haloimines 2c and 2j, [RuCl2(p-
cymene)]2 (28 mg, 0.045 mmol) and 2-amino-2-methylpropan-1-ol (8 mg, 0.090 mmol) were used}. 
During this heating period, the initially orange reaction mixture turned into a dark red color. The 
reaction was then cooled to 50 °C, and a solution of the haloimine 2a-2j or ent-2e (0.9 mmol) in i-
PrOH (6.3 mL) and tert-BuOK (1.13 mL of a 0.1 M solution in i-PrOH, 0.113 mmol) were 
successively added [for aliphatic haloimines 2c and 2j, tert-BuOK (2.25 mL of a 0.1 M solution in i-
PrOH, 0.225 mmol) was used]. After completion of the ATH reaction (generally 2 h, monitored by 
TLC), tert-BuOK (3.9 mL of a 0.3 M solution in i-PrOH, 1.17 mmol) was added to the reaction 
mixture and it was stirred for 1 h at 50 ºC. Then, the reaction mixture was passed through a small 
column of silica gel, the column was washed with ethyl acetate, the combined organic phases were 
evaporated and the resulting residue was purified by column chromatography (silica gel, 
hexane/ethyl acetate), giving the expected N-protected aziridines 4a-4c and pyrrolidines 4d-4j and 
ent-4e with the yields and diastereomeric ratios indicated in Scheme 4. Compounds 4a,7a 4b,7a 4c,6c 
4d,7d 4e,6f ent-4e,6f 4f,7d 4g7d and 4i7d were identified by comparison of their physical and 
spectroscopic data with the ones reported in the literature. The corresponding physical, spectroscopic 
and analytical data for compounds 4h and 4j follow. 
 
(RS,R)-N-(tert-Butylsulfinyl)-2-(2-naphthyl)pyrrolidine (4h): white solid; mp 118 ºC; Rf 0.32 
(hexane/ethyl acetate: 2/1); [α]D20 +237.0 (c 1.5, MeOH, 98:2 dr); IR (neat) 3056, 1095, 1058 cm-1; 
1H NMR (400 MHz, CDCl3) δ 1.05 (9H, s), 1.77-1.96 (3H, m), 2.14-2.28 (1H, m), 3.62 (1H, dt, J = 
10.7, 6.9 Hz), 3.70-3.82 (1H, m), 5.23 (1H, dd, J = 8.2, 2.1 Hz), 7.37 (1H, dd, J = 8.5, 1.6 Hz), 7.40-
7.50 (2H, m), 7.69 (1H, s), 7.73-7.86 (3H, m); 13C NMR (100 MHz, CDCl3) δ 23.0, 24.2, 36.4, 55.1, 
57.4, 57.5, 124.8, 125.0, 125.5, 126.1, 127.6, 127.7, 128.2, 132.3, 133.2, 142.0; m/z (DIP) 301 (M+, 
<1%), 245 (34), 197 (16), 160 (18), 57 (100); HRMS: M+ found 301.1507, C18H23NOS requires 
301.1500. 
 
(RS,R)-N-(tert-Butylsulfinyl)-2-isopropylpyrrolidine (4j): colorless oil; Rf 0.46 (hexane/ethyl 
acetate: 7/3); [α]D20 +19.5 (c 0.9, MeOH, 98:2 dr); IR (neat) 2957, 1470, 1069 cm-1; 1H NMR (400 
MHz, CDCl3) δ 0.89, 0.92 (3H each, 2 d, J = 6.9 Hz each), 1.20 (9H, s), 1.59-1.81 (4H, m), 2.04-
2.16 (1H, m), 3.17-3.26, 3.32-3.41 (1H each, 2 m), 3.57-3.67 (1H, m); 13C NMR (100 MHz, CDCl3) 
δ 16.6, 20.1, 23.4, 25.4, 26.1, 31.0, 50.5, 57.6, 62.7; m/z (DIP) 217 (M+, <1%), 161 (72), 113 (14), 
57 (100); HRMS: M+ found 217.1509, C11H23NOS requires 217.1500. 
 
Removal of the Sulfinyl Group. Isolation of Pyrrolidines 7e and ent-7e. General Procedure 
Product 4e or ent-4e (133 mg, 0.5 mmol) was dissolved in a 2 M solution of HCl in methanol (7 
mL; prepared by dropwise addition of SOCl2 to methanol at 0 ºC) and stirred overnight at room 
temperature. Then, the solvent was evaporated, a 2 M aqueous HCl solution (10 mL) was added and 
the mixture was extracted with ethyl acetate (3 × 10 mL). The organic layers were discarded. The 
aqueous layer was basified with a buffer solution of NH3 (2 M) / NH4Cl (2 M) (10 mL) and a 2 M 
aqueous NaOH solution to ensure pH > 11. The mixture was extracted with CH2Cl2 (3 × 10 mL). 
The combined organic phases were dried (Na2SO4). After filtration and evaporation of the solvent, 
the pure pyrrolidine 7e (78 mg, 97%) or ent-7e (80 mg, 99%) was obtained. Compounds 7e and ent-
7e were identified by comparison of their physical and spectroscopic data with the ones reported in 
the literature.7c 
 
Benzoylation of Pyrrolidines 7e and ent-7e. Determination of the Enantiomeric Excess of 
Compounds 7e and ent-7e 
A solution of 7e or ent-7e (24 mg, 0.2 mmol) in CH2Cl2 (5 mL) was cooled to 0 ºC. An aqueous 2 
M NaOH solution (5 mL) was added, followed by benzoyl chloride (46 µL, 0.4 mmol) and the 
resulting mixture was stirred for 4 h at room temperature. The organic layer was separated, washed 
with an aqueous 2 M NaOH solution (2 × 5 mL) and dried (Na2SO4). Filtration and evaporation of 
the solvent afforded the corresponding benzamide, which was analyzed by HPLC on a ChiralCel 
OD-H column using a 254 nm UV detector, 10% i-PrOH in hexane as eluent and a flow rate of 0.5 
mL/min. The retention times of the two enantiomers were 25.6 min (S) and 29.5 min (R) (see the 
Supporting Information for details). 
 
Two-Step Procedure ATH + Cyclization. Synthesis of Piperidines 4k-4m and Azepanes 4n, 
4o. General Procedure 
Haloimine 2k-2m, 2n’ or 2o’ was reduced by the same ATH procedure used for the preparation of 
aziridines and pyrrolidines (see above). After completion of the ATH process (generally 2 h, 
monitored by TLC), the reaction mixture was directly passed through a small column of silica gel, 
the column was washed with ethyl acetate, and the combined organic phases were evaporated, giving 
halosulfinamide 3k-3m, 3n’ or 3o’, which was submitted to the cyclization step without further 
purification. 
KHMDS (1.17 mL of a 1 M solution in THF, 1.17 mmol) was added to a solution of the 
halosulfinamide 3k-3m, 3n’ or 3o’ (0.9 mmol) in anhydrous THF (4 mL) at 0 ºC. For the synthesis 
of piperidines 4k-4m, the reaction was then stirred for 1 h at 0 ºC. For the preparation of azepanes 
4n and 4o, the cooling bath was removed and the reaction mixture was stirred overnight at room 
temperature. After completion of the cyclization step, Et2O (10 mL) and a saturated aqueous NH4Cl 
solution (5 mL) were added. The mixture was extracted with Et2O (3 × 5 mL) and the combined 
organic layers were dried (Na2SO4). After filtration and evaporation of the solvent, the resulting 
residue was purified by column chromatography (silica gel, hexane/ethyl acetate), giving the 
expected N-protected heterocycles 4k-4o with the yields and diastereomeric ratios indicated in 
Scheme 5. Compound 4k7d was identified by comparison of its physical and spectroscopic data with 
the ones reported in the literature. The corresponding physical, spectroscopic and analytical data for 
compounds 4l, 4m, 4n and 4o follow. 
 
(RS,R)-N-(tert-Butylsulfinyl)-2-(3-methylphenyl)piperidine (4l): colorless oil; Rf 0.51 
(hexane/ethyl acetate: 7/3); [α]D20 +111.0 (c 1.2, MeOH, 99:1 dr); IR (neat) 3045, 1455, 1073 cm-1; 
1H NMR (400 MHz, CDCl3) δ 1.16 (9H, s), 1.39-1.52 (1H, m), 1.54-1.72 (3H, m), 1.97-2.08, 2.15-
2.24 (1H each, 2 m), 2.37 (3H, s), 3.29 (2H, m), 4.63 (1H, t, J = 4.2 Hz), 7.06 (1H, d, J = 6.7 Hz), 
7.19-7.28 (3H, m); 13C NMR (100 MHz, CDCl3) δ 20.4, 21.7, 23.0, 25.6, 31.2, 44.1, 57.3, 58.7, 
124.4, 127.4, 128.1, 128.4, 138.1, 140.1; m/z (DIP) 279 (M+, 7%), 223 (100), 175 (21), 91 (12), 57 
(49); HRMS: M+ found 279.1660, C16H25NOS requires 279.1657. 
 
(RS,R)-N-(tert-Butylsulfinyl)-2-methylpiperidine (4m): yellowish oil; Rf 0.53 (hexane/ethyl 
acetate: 3/2); [α]D20 –36.0 (c 1.0, MeOH, 97:3 dr); IR (neat) 2971, 2932, 1455, 1360, 1073 cm-1; 1H 
NMR (300 MHz, CDCl3) δ 1.17 (9H, s), 1.24 (3H, d, J = 6.5 Hz), 1.42-1.81 (6H, m), 2.77-2.92 (1H, 
m), 3.20-3.40 (2H, m); 13C NMR (75 MHz, CDCl3) δ 19.6, 22.0, 23.4, 26.0, 34.0, 42.3, 55.0, 57.6; 
m/z (DIP) 203 (M+, <1%), 147 (59), 98 (11), 57 (100); HRMS: M+ found 203.1339, C10H21NOS 
requires 203.1344. 
 
(RS,R)-N-(tert-Butylsulfinyl)-2-phenylazepane (4n): white solid; mp 64 ºC; Rf 0.65 (hexane/ethyl 
acetate: 4/1); [α]D20 +271.0 (c 1.7, CH2Cl2, > 99:1 dr); IR (neat) 3062, 1448, 1059 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 1.02 (9H, s), 1.20-1.34, 1.58-1.67, 1.70-1.96, 2.17-2.31 (1H, 1H, 5H and 1H, 
respectively, 4 m), 3.40-3.48 (1H, m), 3.56 (1H, d, J = 15.2 Hz), 4.68 (1H, dd, J = 10.8, 5.7 Hz), 
7.18-7.35 (5H, m); 13C NMR (100 MHz, CDCl3) δ 23.1, 25.3, 29.6, 30.1, 38.9, 48.0, 56.7, 57.8, 
126.3, 126.4, 128.4, 145.4; m/z (DIP) 279 (M+, <1%), 223 (100), 175 (45), 117 (22), 91 (80), 57 
(21); HRMS: M+ − C4H8 found 223.1022, C12H17NOS requires 223.1031. See the Supporting 
Information for X-ray structure details. 
 
(RS,R)-N-(tert-Butylsulfinyl)-2-(3-methoxyphenyl)azepane (4o): yellowish solid; mp 80-81 ºC; Rf 
0.73 (hexane/ethyl acetate: 7/3);  [α]D20 +209.0 (c 0.6, CH2Cl2, 98:2 dr);  IR (neat) 3030, 1579, 1278, 
1063 cm-1; 1H NMR (400 MHz, CDCl3) δ 1.03 (9H, s), 1.17-1.34, 1.57-1.95, 2.19-2.31 (1H, 6H and 
1H, respectively, 3 m), 3.34-3.49 (1H, m), 3.56 (1H, d, J = 15.3 Hz), 3.80 (3H, s), 4.66 (1H, dd, J = 
10.9, 5.7 Hz), 6.74 (1H, dd, J = 8.2, 2.3 Hz) 6.78-6.88 (2H, m), 7.23 (1H, t, J = 7.9 Hz); 13C NMR 
(100 MHz, CDCl3) δ 23.1, 25.2, 29.7, 30.0, 38.8, 48.1, 55.1, 56.5, 57.8, 111.3, 112.3, 118.7, 129.5, 
147.1, 159.6; m/z (DIP) 309 (M+, <1%), 253 (100), 205 (39), 57 (43); HRMS: M+ − C4H8 found 
253.1132, C13H19NO2S requires 253.1136. 
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